Drug Trial Radar · NCT07494045
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants
Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Aug 5, 2026
Primary completion
Oct 2027
Study completion Aug 2028
Sponsor
- Lead sponsor
- OPKO Health, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 month, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate safety, tolerability, and how CTAP101 Capsules work to treat Pediatric Participants with Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency. The main questions it aims to answer are: 1. To assess the pharmacokinetics (PK) and Pharmacodynamics (PD) of CTAP101 Capsules 2. To investigate the safety and tolerability of CTAP101 Capsules Participants will take a daily dosage of CTAP101 Capsules at bedtime for 8 weeks.
Conditions
- CKD Stage 3
- CKD Stage 4
- Secondary Hyperparathyroidism
- VDI
Interventions
CTAP101Drug
Capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Apparent clearance (CL/F)Time frame: Up to 14 weeks
- Volume of distribution (Vd/F)Time frame: Up to 14 weeks
- Terminal elimination half-life (t1/2)Time frame: Up to 14 weeks
- Incidence of treatment emergent adverse events (TEAE)Time frame: Up to 14 weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
OPKO Site
Kansas City, Missouri · Not yet recruiting
OPKO Site
Columbus, Ohio · Not yet recruiting
OPKO Site
Philadelphia, Pennsylvania · Not yet recruiting
OPKO Site
Greenville, South Carolina · Recruiting
OPKO Site
Madison, Wisconsin · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.